therapeutics" Corporate Overview April 2023 Disclaimer and Safe Harbor Statement | 2 케어 TANGO Tango summary First clinical trial ongoing and three IND filings planned for 2023 • TNG462 phase 1/2 trial initiation expected mid-2023 - a next generation MTA-cooperative PRMT5 inhibitor | --- | --- | --- | --- | --- | |------------------------------------------------|-------|-------|-------|-------| | | | | | | | Targeting tumor suppressor loss | | | | | | to unmask vulnerabilities in cancer | | | | | | for the n ...

Pipeline and Milestones - Tango Therapeutics expects to initiate a Phase 1/2 trial for TNG462, a next-generation MTA-cooperative PRMT5 inhibitor, in mid-2023[1] - The company plans to file an IND for TNG348, a USP1 inhibitor targeting BRCA1/2 mutant and other HRD+ cancers, in mid-2023[1] - Tango Therapeutics anticipates an initial clinical update for TNG908 in Q2 2023[106] - Tango Therapeutics plans to file an IND for TNG260, a CoREST inhibitor, in the first half of 2023[84, 106] Strategic Partnerships and Financials - Tango Therapeutics has a strong strategic partnership with Gilead[2] - The partnership with Gilead includes $175 million upfront, $20 million in equity, and up to $6 billion in milestones[107] - Tango Therapeutics has sufficient cash to fund operations into 2025[106, 127] Drug Programs and Mechanisms - TNG462 is reported to be approximately 30 times more potent than TNG908 and 45 times more selective for MTAP deletion[10] - TNG462 has an IC50 of 4 nM and 45X selectivity for MTAP deletion[56, 63] - TNG908 is brain penetrant and potentially active in GBM patients[10] - TNG908 demonstrates 15X selectivity for MTAP deletion with an IC50 of 110 nM[35, 163] - TNG260 has an IC50 of 5nM and 10X CoREST complex selectivity[49]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHaANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39485 TANGO THERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation ...

| --- | --- | --- | --- | --- | |------------------------------------------------|-------|-------|-------|-------| | | | | | | | Targeting tumor suppressor loss | | | | | | to unmask vulnerabilities in cancer | | | | | | for the next generation of precision medicines | | | | | | 1 Certain statements in this presentation may be considered forward-looking statements. Forward-looking statements generally relate to future events, Tango's future financial and operating performance, goals, expectations, beliefs, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number: 001-39485 (857) 320-4900 (Registrant's telephone number, including area code) Securities registered p ...

therapeutics" | --- | --- | --- | --- | |------------------------------------------------|-------|-------|-------| | | | | | | Targeting tumor suppressor loss | | | | | to unmask vulnerabilities in cancer | | | | | for the next generation of precision medicines | | | | Corporate Overview August 2022 | 1 Disclaimer and Safe Harbor Statement Certain statements in this presentation may be considered forward-looking statements. Forward-looking statements generally relate to future events, Tango's future financi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 (State or other jurisdiction of incorporation or organization) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number: 001-39485 TANGO THERAPEUTICS, INC. (Exact N ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number: 001-39485 TANGO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) (State or other ...

therapeutics" | --- | --- | --- | --- | --- | |------------------------------------------------|-------|-------|-------|-------| | | | | | | | Targeting tumor suppressor loss | | | | | | to unmask vulnerabilities in cancer | | | | | | for the next generation of precision medicines | | | | | Corporate Overview April 2022 Confidential | 1 Disclaimer and Safe Harbor Statement Certain statements in this presentation may be considered forward-looking statements. Forward-looking statements generally relate to fut ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR Washington, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO FORM 10-K Commission File Number 001-39485 TANGO THERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) (Mark One) Delaware 85-1195036 (State or other jurisdiction of incorporation or organization) 100 Binney St., Suite 700 Cambridge, MA 02142 (Address of principal executive offices) (Zip Cod ...